Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
暂无分享,去创建一个
G. Sethuraman | A. Dinopoulos | Gopalan Sethuraman | David Neal Franz | Jennifer Leonard | Cynthia Tudor | Gail Chuck | Marguerite Care | Argirios Dinopoulos | George Thomas | Kerry R Crone | D. Franz | Marguerite M. Caré | M. Caré | C. Tudor | J. Leonard | G. Chuck | G. Thomas | K. Crone | Marguerite M. Care
[1] Hongbing Zhang,et al. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. , 2004, Cancer research.
[2] G. Schmid,et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. , 2005, Blood.
[3] G. Watkins,et al. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. , 2005, European journal of cancer.
[4] Hongbing Zhang,et al. Perturbed IFN-γ-Jak-Signal Transducers and Activators of Transcription Signaling in Tuberous Sclerosis Mouse Models , 2004, Cancer Research.
[5] B. Scheithauer,et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Angelo Nicolin,et al. mTOR: a protein kinase switching between life and death. , 2004, Pharmacological research.
[7] R. McLendon,et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. , 2005, Molecular cancer therapeutics.
[8] Donghui Li,et al. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. , 2005, Biochemical and biophysical research communications.
[9] M. Delgado,et al. Early Diagnosis of Subependymal Giant Cell Astrocytoma in Patients With Tuberous Sclerosis , 1998, Journal of child neurology.
[10] A. Medhkour,et al. Neonatal Subependymal Giant Cell Astrocytoma , 2002, Pediatric Neurosurgery.
[11] D. Kwiatkowski. Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis , 2003, Cancer biology & therapy.
[12] J. Piatt,et al. Spontaneous Involution of a Diencephalic Astrocytoma , 1998, Pediatric Neurosurgery.
[13] B. Law,et al. Rapamycin: an anti-cancer immunosuppressant? , 2005, Critical reviews in oncology/hematology.
[14] E. Raymond,et al. mTOR-targeted therapy of cancer with rapamycin derivatives. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] D. Gutmann,et al. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. , 2005, Cancer research.
[16] David M Sabatini,et al. An expanding role for mTOR in cancer. , 2005, Trends in molecular medicine.
[17] Paul Tempst,et al. Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.
[18] G. Gores,et al. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. , 2005, Seminars in liver disease.
[19] C. Shields,et al. Aggressive retinal astrocytomas in four patients with tuberous sclerosis complex. , 2004, Transactions of the American Ophthalmological Society.
[20] A. Duhaime,et al. Subependymal giant cell astrocytomas in children. , 1994, Pediatric neurosurgery.
[21] Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779. , 2004, Drugs in R&D.
[22] R. Yeung,et al. Effects of Rapamycin in the Eker Rat Model of Tuberous Sclerosis Complex , 2005, Pediatric Research.
[23] K. Hess,et al. Mechanisms of action of rapamycin in gliomas. , 2005, Neuro-oncology.
[24] I. Tannock,et al. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. , 2005, Cancer research.
[25] R. Packer,et al. Spontaneous Regression of Low-Grade Astrocytomas in Childhood , 2000, Pediatric Neurosurgery.
[26] Shile Huang,et al. Mechanisms of resistance to rapamycins. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[27] P. Lindnér,et al. Inhibition of mTOR suppresses experimental liver tumours. , 2005, Anticancer research.
[28] Shiuan Chen,et al. Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer , 2005, Clinical Cancer Research.
[29] H. Takimoto,et al. Glioblastoma following radiotherapy in a patient with tuberous sclerosis. , 1998, Neurologia medico-chirurgica.
[30] S. Dashti,et al. Pineal region giant cell astrocytoma associated with tuberous sclerosis: case report. , 2005, Journal of neurosurgery.
[31] G. Thomas,et al. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb. , 2004, Novartis Foundation symposium.
[32] A. Taratuto,et al. Subependymal giant cell astrocytoma in children with tuberous sclerosis , 2003, Child's Nervous System.